Member Info for sadoldgit

Triple negative breast cancer is a billion dollar market with poor prognosis.

The use of nano particles to effectively better target the indication is a monumental leap forward and with the addition of being used in conjunction with Ultrasound has produced outstanding results, again in preclinical and head and shoulders above any current treatment.

Interesting that these results produced just after GSK took over SO. Highly unlikely to know if these investigational combo therapies were in place.

Has Sareum received a message in a chinese accent wanting to speak to a Mr Tim or the CPF in similar.

This really does take the ball game to a whole new level with regards, to an effective treatment, in what is at present a very difficult cancer to treat.

As far as i know the compounds can be used in preclinical trials but not administered to humans as that would require approval.
Approval for clinical trial. Looks like SO have well and truly 5hit out.

We now have
737 with LDG
737 with LDG and PD-1
737 with PARPi
Now 737 with doxorubicin with Ultrasonic activation to effectively target therapy.
Interesting times ahead.

Brilliant find HbD!

I'm assuming it's the first entry under the CHK1 heading (CN104302635) at http://www.sareum.com/news/patents-and-publications/

This compound is definitely CCT245737.

I cannot remember a Chinese patent being granted for CHK1 in China via RNS. I know patents were made for our Aurora plus FLt3 around this time.

https://worldwide.espacenet.com/publicationDetails/description?CC=CN&NR=104169277B&KC=B&FT=D&ND=4&date=20161012&DB=worldwide.espacenet.com&locale=en_EP#

RNS from Sareum
http://www.sareum.com/news/press-releases-and-news/2016/china-and-hong-kong-patent-grants-sareums-auroraflt3-kinase-inhibitors/

This is not far from the time that shows the CCT245737 patent in China.

Maybe the patents where filed by Cancer Research Therapeutics.

Maybe just an error in documenting as Aurora FLT+3 was granted patent in Oct 2016.

Maybe the RNS released on 3rd of August should have stated patent grant for CCT245737 and not Aurora FLT+3.

That is a great and very interesting find HbD.

https://topic.echemi.com/a/chk1-inhibitors-bibert-pharmaceuticals-class-1-new-drugs-were-approved-clinically_106314.html

This taken from Chinese to Englsh translation, may I therefore suggest that approved clinically actually means approved for clinical trial use.
It is IV administered.

There is also a mention of SRA737 in AACR journals. Fairly recent January 15th this year.

https://aacrjournals.org/clincancerres/article/29/2/331/713982/A-Phase-I-II-Trial-of-Oral-SRA737-a-Chk1-Inhibitor

There are some updates as this information has previusly been available for quite a few months.

Regards

Good day SCHeckler.
As an overview of SRA 737 in preclinical take a butchers at the link below.
You can scroll down most of it and just read up pertinent info.

Click on combination treatment of CHK1 (That will be 27 Aug 2019)

https://www.jto.org/article/S1556-0864(19)30692-6/fulltext
Quite impressive preclinical efficacy.

Patent protection I am finding very confusing to establish exactly what and where 737 is protected.

There exists a plethora of drugs available for clinical use at the moment with many being used alone or in combo therapy in Oncology.

SRA 737 whilst not compatible with everything out there at the moment is potentially compatible with many treatments such as PARPi, PD-1, and Wee1 inhibitors and yes is also very compatible with Gemcitabine.
It is where 737 will fit in especially regards to in combo therapy that will ultimately decide value along with associated patent protection.

Slight deviation here is Edison valuation of SRA737
18 Sep 2017 · We value SRA737 at $119.4m based on a 15% probability of success,
From memory this was based on patent coverage up to 20319 ( expiry of patent) and one 6th share of a projected 1 billion dollar final year worldwide market value.

Unable to access this further.
I can access more on mobile phone under Edison report 2017 a much longer review SO valuations and increase in SP due to probability of success being increased from 15 to 25%.
This around 2018 so prior to any developed preclinical studies data.

Note this is before and results of phase trials in mono or with LDG completion.
It were postulated that SRA 737 maybe of benefit in other combinations.

Regards

I believe the 5 to 10 days gunner is to register for CTN. Then around 1 to 3 months for Ethical review result.

There exists over 200 different cancers. Some treatments will be more effective in some areas than others. Eventually, over time cancers will develop resistance to a particular treatment rendering the treatment ineffective.

https://www.cancernetwork.com/view/gemcitabinecarboplatin-combination-regimens-importance-dose-schedule

https://www.linkedin.com/pulse/cisplatin-history-old-yet-vitally-important-drug-field-adams-phd#:~:text=Therefore%2C%20DNA-crosslinking%20by%20cisplatin%20causes%20DNA%20damage%20and,the%20reason%20clinicians%20still%20use%20this%20drug%20today.

https://pubmed.ncbi.nlm.nih.gov/30771522/

https://pubmed.ncbi.nlm.nih.gov/28490518/

There exists over 200 different cancers. Some treatments will be more effective in some areas than others. Eventually, over time cancers will develop resistance to a particular treatment rendering the treatment ineffective.

https://www.cancernetwork.com/view/gemcitabinecarboplatin-combination-regimens-importance-dose-schedule

https://www.linkedin.com/pulse/cisplatin-history-old-yet-vitally-important-drug-field-adams-phd#:~:text=Therefore%2C%20DNA-crosslinking%20by%20cisplatin%20causes%20DNA%20damage%20and,the%20reason%20clinicians%20still%20use%20this%20drug%20today.

https://pubmed.ncbi.nlm.nih.gov/30771522/

https://pubmed.ncbi.nlm.nih.gov/28490518/

Regarding patents.
The chinese now have a CHK1 inhibitor and using in combo with LDG. They are mow looking at triple combo with strikingly similar combinations as were SO.
Of course only available in China at the moment as that it is where it has been approved for clinical use.
How big a protection in combo does SRA737 have and in which territories does it apply?

I believe it was a point hence why GSK /SO not take on board. Coming close to a 4 year delay now.
To which compound are you referring to as generic?
If it is Cisplatin it now totally irrelevant. Far too much toxicity. Done and dusted.
I would hazard a well educated guess, that this was done on the back bone of sierra possible commercialisation and patent. Maintains the value of cisplatin if combo patent on success.

Michelle Garrett much involved at later stages of combination therapies involved with 737 and platinum based therapies certainly not one of them. Also an advisor to SO. Are you aware of that? MG involved from day 1 of development of CHK1 inhibitors. So much work she has undertaken. Also at later stage Triparna Sen.
I have posted links many times before.
MG never entered in to any platinum based chemo therapy investigations in combo with 737.

'So as I understand it, it’s dusting down an old product for which the patent has expired and novating the patent as a combo. As a result - the combo becomes a serious revenue earner.

Gemcitabine is a generic chemo and proved good results in stage 2 trials with 737 alone.'

I never mentioned gemcitabine, or to be precise LDG in combo.

Lack of detail here to give your comment any credibility.

Look forward to your views on this

Preclinical in combo in SCLC way above anything else available at the moment, ie LDG 737 and a programmed death inhibitor which can be PD-1 or PD-L1 I take it you understand the difference.
So what is this dusted down compound you refer to with patent expired?

If it is gemcitabine then you have well and truly missed my point. I merely referred to combo involving Cisplatin. indeed 737, cisplatin and LDG were involved at some stage. The point I were making relates to the trial of 737 in combo with Cisplatin.

SRA737 as a mono therapy is not a money spinner from a commercial point of view. Basically on how a CHK1 inhibitor works.

That is the point and a giant enormous one at that.

Regards

No need for either HbD. I forgot to add or vica versa.

Regards

Regarding 737 and 1802. My opinion again is that for this to take place there would have to be a reason.
What is the current pipeline of the interested Pharma?
Anyone that takes on both 737 and 1802 needs deep pockets.
If your business has enough then complete buyout of SDC1801 SDC, 1802 and our 27.5% of 737.
Opened a tin of worms here.

To buyout complete you need put value on compounds.
Value can only be established once certain levels are reached and elements of risk removed.

SDC 1801 needs as a minimum of Phase 1 a results to establish safety.
This will look good for 1801 and 1802 if are at least as good as to what TIm an co as well as a few of LTH expect.

Go further and put SDC into Psoriasis and see what the results are. Our efficacy should at least be the same as Deucravacitinib if not substantially better. with regards to safety that can subject to considerable debate.

If the above all become favourable proven then 10 times current SP will not be beyond any reasonable expectation.

One for Thoth2 here bless is heart. If all comes good £28 a share not out of question albeit many moons away. Circa 2 billion.

Bare in mind this is not going to happen overnight!

Yes there does exist risk as many newly claimed long term holders proliferate.

How many of these newly claimed LTH's make any positive indications as to just how much potential this company actually has?

None! Look at their posting history.
Regards

An on license HbD would still enable us to 27.5%. This cannot be legally be sold to any other party without the consent of Sareum for which any interested party would need to negotiate directly to Sareum.

Regards
On license in a sense is best in current economic climate I feel.

HbD you are on my level of thinking

There has been very little financial input for cancer diagnosis. Hard to treat cancers only have or have had about 16.5 % funding compared to other cancers.

Yes, this is a cause for concern. Early diagnosis is of the upmost importance in any disease especially cancer which can harbour for years.

It's a very complex issue.
Pharmaceuticals will want to make as much money as they can. Once a compound has been given approval in an indication it will then be pushed in other indications (commercialisation).

Yes it is in areas of hard to treat cancers that 737 has been aimed at. If we are interested in treating the cancer then it ought to be a level playing field.
it was used in studies whereby patients have advanced/ metatastic cancer and stages of cancer that previous treatments were no longer effective.
i will post some links over the weekend with regards to CHK1 inhibitors and work undertaken by Michelle Garrett.
Ask yourself a question, would a big pharma welcome a competitor like 737 in triple combination therapy up against its already paid for pipeline?

I will add that in stage 2 trials there were those that did benefit and continued on treatment after end of trial period. Not many I may add and again from memory only.
Advanced HGSOC has 98% P53 checkpoint prevalence.

Very significant results in ano genital cancer ( for which there is a demand) and further preclinical in combo with SCLC.

Current economic climate not good. I still see as a minimum of 20 million upfront for a licencing deal of which sareum entitled to 27.5% of.
Circa 5.5 milllion but would increase the market cap value considerably more.
Should we take it of the original Edison placed value of as it stood then prior to Phase 2 results at 120 million dollars and as far as I know end points were met or would not continue further studies including preclinical we looking at circa 600 million.

This would be current value. Up front payment 5 to 10% and heavily loaded back end milestones and royalties.

The need for funding for 1b 1801 and continuation of translational studies 1802 would nigh be resolved. SP would be higher and at this time if chosen so maybe the raising of funds to develop 1802 into early stage trials.

Nothing is guaranteed. If it were the SP would be substantially much higher than as it stands now.
Regards

Whoops genetic it should read and not generic.
Apologies.

007, i would presume Utah looking to get back in at 90. Wow 15% but I suppose not to be sneezed at.
A possibility here is an RNS may land any day from now on with regarding on licence to 737.
CPF are at the helm.
Tim stated options to 'rapid on license' or further development and then on licence.
It is getting close to a month since finalisation of data returned. 1 day to a month to analyse generic data.
There have been at least 3 approaches about 737. This has taken place before 16th Dec. That we know.
All rights returned to CPF as we know by notification of intent Jan 12th.

Discussions will have evolved.
There exists more than one party.

Unless an acceptable financial deal was materialising, then in my opinion we would have been notified of decision to further develop and then on licence. Maybe a buyout altogether but doubt that as the norm is to on licence.
Prior to completion of receiving all data, communications involving deal packages/ on licensing and pricing subject to generic data results would have already been made or at least at very late stage by now.

One thing I will add is that should some difficult to treat cancers become diagnosed at an earlier stage then the outlook for 737 will look very favourable indeed, long term.

Regards

Good morning peeps.

Has anyone ever considered the stage 1 & 2 trials of SRA737.
In mono very mediocre
LDG around 25% overall response rate in tumour reduction across the board. Note High grade Serious Ovarian cancer very difficult to achieve. Dont take theses figures as exact as just from memory. The important aspect here is the stage ( or to be more precise the time in the development of the cancer that SRA737 was used to treat patients)
At late stage indicated by the selection criteria that patients must have at least 12 weeks life expectancy to participate in trials. In addition most of these patients would have received previous forms of treatment for these cancers that are no longer effective. This in a nutshell indicates that the cancer has already developed resistance to these treatments via the use of alternate pathways.
It would therefore be reasonable to conclude that had 737 been administered at an earlier stage then the overall response rate would have been much higher. This is my thinking on the matter so do not take as gospel.

Trial in combination with cisplatin showed no significant improvement. Cisplatin ( platinum based therapy) has been around many years ( first approved 1978). Cisplatin has associated toxicities and as such I feel would not be granted approval in the modern world. Cisplatin is used as a chemo to treat some similar indications as to 737.

From a health care advisor ( not medically qualified):-

'I dont explain how it works as I am not qualified medically but I will explain my experience while treating my father who was suffering from cancer (gallbladder and Bile duct)
In my experience, this is dangerous for treating advanced stage patient. family of platinum based drugs have very strong affect on patients immunity

If patient is old with advanced cancer grown to multiple organs, this medicine will have adverse effects'.

Phase 2 trials with 737 as far as I can tell involved older patients.
It would not be unreasonable to conclude that those that took part had very little apart from hope.
A link to cisplatin below
https://www.ncbi.nlm.nih.gov/books/NBK547695/

Back to 737.
However, one thing we do know is the significant increase in efficacy when used in triple combo inclusive of a PD-1 inhibitor ( preclinical). Yes, this includes LDG which is an iv administered chemo.

https://patient.info/news-and-features/less-survivable-cancers-are-more-likely-to-have-a-late-diagnoses#:~:text=These%20disproportionate%20late%20stage%20cancer%20diagnoses%20make%20it,given%20how%20rapidly%20the%20cancer%20cells%20can%20spread.

https://www.globenewswire.com/news-release/2021/05/07/2225189/0/en/Checkpoint-Kinase-Inhibitor-Pipeline-Analysis-Key-Pharma-Companies-and-Emerging-Therapies-Offering-New-Horizons-in-Cancer-Care.html

Regards